Enrolling by invitationPHASE2, PHASE3NCT05883748
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Studying Autosomal erythropoietic protoporphyria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Disc Medicine, Inc
- Principal Investigator
- Will Savage, MD PhDDisc Medicine
- Intervention
- DISC-1459(drug)
- Enrollment
- 230 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2023 – 2028
Study locations (13)
- University of Alabama Hospital, Birmingham, Alabama, United States
- University of California San Francisco, San Francisco, California, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- MetroBoston Clinical Partners, Boston, Massachusetts, United States
- Mount Sinai Hospital, New York, New York, United States
- Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
- Remington-Davis Clinical Research, Columbus, Ohio, United States
- Einstein Medical Center, Philadelphia, Pennsylvania, United States
- University of Texas, Galveston, Texas, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- The Royal Melbourne Hospital, Parkville, Victoria, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05883748 on ClinicalTrials.gov